Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01537861
First received: February 15, 2012
Last updated: October 17, 2014
Last verified: October 2014

February 15, 2012
October 17, 2014
June 2012
February 2014   (final data collection date for primary outcome measure)
Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma. [ Time Frame: Up to 30 days after last treatment ] [ Designated as safety issue: Yes ]
Number and grade of adverse events based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Safety of the combination of G-CSF and bortezomib with or without dexamethasone in patients with bortezomib-refractory multiple myeloma. [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
Number and grade of adverse events based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Complete list of historical versions of study NCT01537861 on ClinicalTrials.gov Archive Site
  • Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow [ Time Frame: 14 days after last drug treatment ] [ Designated as safety issue: No ]
  • Response rate as defined by the International Myeloma Working Group (IMWG) criteria [ Time Frame: 14 days after last drug treatment ] [ Designated as safety issue: No ]
  • Overall survival duration of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the date of first dose of study drug to the date of death from any cause.
  • Progression-free survival of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the interval from the date of first treatment to date of first documentation of disease progression.
  • Duration of response of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the interval from the date of first documentation of response to the first documentation of disease progression.
  • Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • Response rate as defined by the International Myeloma Working Group (IMWG) criteria [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • Overall survival duration of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the date of first dose of study drug to the date of death from any cause.
  • Disease-free survival of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the interval from the date of first documentation of a disease free state to date of recurrence or death due to any cause.
  • Remission duration of patients treated on study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Defined as the interval from the date complete remission is documented to the date of recurrence.
Not Provided
Not Provided
 
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma cells, depriving them of key support signals and rendering them more sensitive to chemotherapy. The investigators therefore propose to do an initial pilot study 1) to explore the safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with bortezomib-, carfilzomib-, or IMID-refractory myeloma and 2) to generate correlative data for a subsequent larger study looking at the combination.

Not Provided
Interventional
Phase 0
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Filgrastim
    Other Names:
    • G-CSF
    • Neupogen®
    • Granulocyte Colony-Stimulating Factor
  • Drug: Bortezomib
    Other Name: Velcade®
  • Drug: Carfilzomib
    Other Name: Kyprolis®
  • Drug: Dexamethasone
  • Drug: Cyclophosphamide
    Other Name: Cytoxan
  • Drug: Thalidomide
    Other Name: Thalomid
  • Drug: Lenalidomide
    Other Name: Revlimid
  • Drug: Pomalidomide
    Other Name: Pomalyst
Experimental: Arm 1

Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.

Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.

Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.

PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen.

Interventions:
  • Drug: Filgrastim
  • Drug: Bortezomib
  • Drug: Carfilzomib
  • Drug: Dexamethasone
  • Drug: Cyclophosphamide
  • Drug: Thalidomide
  • Drug: Lenalidomide
  • Drug: Pomalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
7
December 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must have a confirmed diagnosis of multiple myeloma. The patient may be any stage of multiple myeloma. The patient may have received one or more lines of prior therapy (there is no limit to number of prior lines of therapy permissible).
  • Patient must be ≥18 years of age
  • Patient must be in active treatment with one of the following:

    • twice-weekly bortezomib (on Days 1, 4, 8, and 11 of a 21-day cycle) with or without dexamethasone
    • carfilzomib (on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle) with or without dexamethasone
    • an IMID with or without dexamethasone daily on Days 1 to 21.
    • Patients being treated with bortezomib or carfilzomb may also be receiving an IMID or PO cyclophosphamide with the regimen.
  • Patient must have shown stable or progressive disease on the current bortezomib-, carfilzomib-, or IMID-containing regimen with a measurable monoclonal protein component in the serum (at least 0.5 g/dl on electrophoresis or 0.05 g/dl [50mg/dl] on serum-free-light-chain). Patients who had an initial response on the current bortezomib-, carfilzomib-, or IMID-containing regimen but now have stable (plateaued) disease are eligible.
  • Patient must have an ECOG performance status of 0 - 2
  • Patient must be receiving concurrent treatment with bisphosphonates, with one dose occurring within 30 days prior to first day (Day -3) of protocol treatment
  • Patient must have acceptable hematologic parameters, defined as:

    • Absolute neutrophil count > 1000 cells/mm3
    • Platelets ≥ 50,000 cells/mm3
    • Hemoglobin ≥ 8 g/dl
  • Patient must have adequate liver function, defined as:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal
    • Total bilirubin < 2 x upper limit of normal
  • Patient must be able to understand and willing to sign a written informed consent document

Exclusion Criteria:

  • Patient must not be receiving any agents with known or suspected anti-myeloma activity (other than bortezomib, carfilzomib, dexamethasone, an IMID or PO cyclophosphamide, and bisphosphonates with the current regimen)
  • Patient must not be actively using myeloid growth factors
  • Patient must not have had any prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years
  • Patient must not have any uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary disease, and symptomatic heart failure
  • Patient must not have neuropathy ≥ grade 3 or painful neuropathy ≥ grade 2 (NCI CTCAE v 4.0)
  • Patient must not have any known active infections requiring IV antibiotic, antiviral, or antifungal therapy
  • Patient must not be pregnant or breastfeeding
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01537861
201204086
No
Washington University School of Medicine
Washington University School of Medicine
Not Provided
Principal Investigator: Ravi Vij, M.D. Washington University School of Medicine
Washington University School of Medicine
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP